RE: Full Ask & NT1 Nov 2024 10:29
I'm not surprised KingH, I've just checked myself and you're right
Add in the NASDAQ/DoseMeRx dosing app which you think could be worth £££mln?
£650,000 cash and huge growth
In the presentation they talked of longer and more substantial opportunities for contracts from the new division
The average contract size has almost trebled over the last 12mths so it's not beyond realms of possibly that PYC could soon be winning £200k-400k + long term contracts going forward
This was from results to June 2024
Implementation of the Company’s Personalised Dosing Software onto DoseMe’s newly launched platform, allowing access to the software for research purposes initially, with the aim to add paid for functionality later• Awarded two large contracts exceeding £286k, in aggregate, with two new clients, one of whom is at the forefront of AI driven drug discovery• Follow-on contracts with Bicycle Therapeutics, Numab Therapeutics, Merck KGaA and Sheffield University exceeding, in aggregate, £822k• Continued operational build of a Biosta